UNASSIGNED:观察血必净联合乌司他丁治疗创伤性脓毒症的疗效及对患者炎性因子和免疫功能的影响。
UNASSIGNED:选取2017年6月至2021年9月我院收治的外伤性脓毒症患者182例。将患者分为对照组和观察组。两组患者均给予初始复苏等常规治疗,输血,监测乳酸以指导液体更换,早期控制感染源,选择合适的抗生素,纠正酸中毒,原发疾病的治疗,预防体温过低和应激性溃疡,血管活性药物的应用,糖皮质激素和营养支持的应用。对照组在常规治疗的基础上给予血必净注射液治疗,观察组在常规治疗的基础上给予血必净注射液联合乌司他丁治疗。采用APACHEⅡ评分对患者治疗前后进行评估,和血常规指标,炎症因子指标,免疫功能指标和肝功能指标进行检测。
未经批准:治疗后,观察组的APACHEⅡ评分(10.35±3.04)低于对照组(15.93±4.52)(P<0.05)。治疗后,观察组白细胞和中性粒细胞(15.19±2.91)和(0.65±0.04)分别低于对照组(16.42±3.44)和(0.79±0.05),PLT(162.85±43.92)高于对照组(122.68±36.89)(P<0.05)。治疗后,血清PCT水平,观察组IL-6、TNF-α分别为(11.38±3.05),(10.74±3.82)和(9.82±2.35)低于对照组(17.34±3.29),(15.28±4.05)和(13.24±3.06)(P<0.05)。治疗后,CD3+的水平,CD4+,CD8+,观察组CD4+/CD8+分别为(50.64±4.98),(40.56±4.82),(27.22±3.29),(1.49±0.24)高于对照组(46.08±4.75),(34.69±4.08),(25.14±3.18),(1.38±0.19)(P<0.05)。治疗后,观察组TBIL和AST水平分别为(12.35±3.82),(25.66±4.49)低于对照组(18.43±4.06),(34.58±5.06)(P<0.05)。
UNASSIGNED:乌司他丁联合乌司他丁治疗外伤性脓毒症患者有较好的疗效,可以有效改善病情,减少身体的炎症反应,促进患者免疫功能和肝功能的恢复。
UNASSIGNED: To investigate the efficacy of
xuebijing combined with ulinastatin in the treatment of traumatic sepsis and analyze the effects on inflammatory factors and immune function of patients.
UNASSIGNED: 182 patients with traumatic sepsis were selected from June 2017 to September 2021 in our hospital. The patients were divided into the control group and the observation group. Patients in both groups were given routine treatments such as initial resuscitation, blood transfusion, monitoring of lactic acid to guide fluid replacement, early control of infection source, selection of appropriate antibiotics, correction of acidosis, treatment of primary disease, prevention of hypothermia and stress ulcer, application of vasoactive drugs, application of glucocorticoid and nutritional support. The control group was treated with
Xuebijing injection on the basis of routine treatment, and the observation group was given
Xuebijing injection combined with ulinastatin treatment on the basis of routine treatment. The APACHE II score was applied to evaluate the patients before and after treatment, and the routine blood indicators, inflammatory factor indicators, immune function indicators and liver function indicators were tested.
UNASSIGNED: After the treatment, the APACHE II score of the observation group was (10.35 ± 3.04) lower than that of the control group (15.93 ± 4.52) (P < 0.05). After treatment, the WBC and neutrophils in the observation group (15.19 ± 2.91) and (0.65 ± 0.04) were lower than those in the control group (16.42 ± 3.44) and (0.79 ± 0.05), and the PLT(162.85 ± 43.92) was higher than that in the control group (122.68 ± 36.89) (P < 0.05). After treatment, the levels of serum PCT, IL-6, TNF-α in the observation group were (11.38 ± 3.05), (10.74 ± 3.82) and (9.82 ± 2.35) lower than those in the control groups (17.34 ± 3.29), (15.28 ± 4.05) and (13.24 ± 3.06) (P < 0.05). After treatment, the levels of CD3+, CD4+, CD8+, CD4+/CD8+ in the observation group were (50.64 ± 4.98), (40.56 ± 4.82), (27.22 ± 3.29), (1.49 ± 0.24) higher than those in the control groups (46.08 ± 4.75), (34.69 ± 4.08), (25.14 ± 3.18), (1.38 ± 0.19) (P < 0.05). After treatment, the levels of TBIL and AST in the observation group were (12.35 ± 3.82), (25.66 ± 4.49) lower than those in the control group (18.43 ± 4.06), (34.58 ± 5.06) (P < 0.05).
UNASSIGNED: Xubijing combined with ulinastatin has a good effect in the treatment of patients with traumatic sepsis, which can effectively improve the condition, reduce the body\'s inflammatory response, and promote the recovery of patients\' immune function and liver function.